Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Fate Therapeutics, Inc. (FATE) had Consolidated Net Income/Loss of $-31.21M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
$1.30M |
|
$-31.21M |
|
-- |
|
$1.30M |
|
$34.30M |
|
$-33.00M |
|
$1.79M |
|
$-31.21M |
|
$-31.21M |
|
$-31.21M |
|
$-31.21M |
|
|
Consolidated Net Income/Loss |
$-31.21M |
$-31.21M |
|
$-33.00M |
|
$-30.85M |
|
120.03M |
|
120.03M |
|
$-0.26 |
|
$-0.26 |
|
| Balance Sheet Financials | |
$179.53M |
|
$54.26M |
|
$105.39M |
|
$284.92M |
|
$30.69M |
|
-- |
|
$74.52M |
|
$105.21M |
|
$179.70M |
|
$179.71M |
|
$179.71M |
|
116.27M |
|
| Cash Flow Statement Financials | |
$-30.82M |
|
$23.59M |
|
-- |
|
$56.85M |
|
$49.62M |
|
$-7.24M |
|
$3.93M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
5.85 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-2540.42% |
|
-2540.42% |
|
-- |
|
-2402.85% |
|
-2402.85% |
|
$-31.06M |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
-- |
|
1.85 |
|
48.78 |
|
-17.37% |
|
-17.37% |
|
-10.96% |
|
-17.37% |
|
$1.55 |
|
$-0.26 |
|
$-0.26 |
|